secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVELATION BIOSCIENCES, INC. (REVB)
CIK:        0001810560
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0000950170-25-067043
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Revelation Biosciences Q1 net loss $2.1M; cash only to June 2025
----------------------------------------------------------------

- Cash and equivalents $3.7M at March 31, 2025, down from $6.5M at Dec 31, 2024.
- Net loss $2.1M ($2.11 per share) vs $2.7M ($39.37 per share) in Q1 2024.
- Operating cash burn $2.8M in Q1 2025, same as Q1 2024.
- Management says current cash sufficient only through June 2025.
- New indication for Gemini in severe burns; topline PRIME Phase 1b data expected summer 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810560/000095017025067043/0000950170-25-067043-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810560/000095017025067043/revb-20250508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-067043

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer